Episode #36: Sensationalizing research, FDA will consider halting TIDE, transcatheter valve-in-valve implant, STEMI treatment variations in Europe, IOM recommends FDA set new standards for salt

This feature requires the newest version of Flash. You can download it here.

For the week ending April 23, we focus on the following heartwire articles:

• This drug kills patients! Avoiding sensationalism in clinical trials

• FDA responds to Senate concerns over rosiglitazone; will "reassess" TIDE trial

• Transcatheter "valve-in-valve" implant for failed bioprosthetic valves is successful in small trial

• STEMI treatment varies considerably across Europe

• IOM recommends FDA set new standards for salt in foods

And, in brief:

• No insurance, money concerns, lead to delays seeking MI treatment

• Intelligent, temperature-dependent antiplatelet drug could reduce bleeding complications

• Public ban on trans fat leads to rapid improvements in health, says BMJ editorial

• Regional variation in cardiac cath rates linked to malpractice concern

Join us for an audio recap of the news that's important to cardiologists this week.

Cite this: Episode #36: Sensationalizing research, FDA will consider halting TIDE, transcatheter valve-in-valve implant, STEMI treatment variations in Europe, IOM recommends FDA set new standards for salt - Medscape - Apr 23, 2010.